Manage Your Liver
Q:

I was diagnosed with NASH about six months ago. I have done a few liver function tests and my ALT level is constantly over the normal range at around 80~100. What exactly is ALT? How important is it for my ALT to stay normal? What can I do to lower my ALT?

A:

ALT (or GPT) is a liver enzyme. Under normal circumstances, this enzyme resides within liver cells. But if the liver is injured, it will causes the liver cells to break and spill the enzymes into the blood stream, raising the enzyme level in the blood. [1] The level of ALT, along with another less significant liver enzyme – AST, are measured in blood tests called liver function tests (LFTs) to detect liver damage.

The normal value of ALT varies among different laboratories, but the common results should be around 10–40 IU/L. [2] An elevated ALT level usually signals liver damage. Long term liver damage and inflammation (as suggested by constantly high ALT) increases the risk of other liver problems. This is because when liver cells are injured, they can repair themselves; but when this happens excessively and repeatedly over time, liver cells may eventually die and scar tissues may form. This is known as fibrosis, which may advance to cirrhosis.

Some scientists found that elevated levels of ALT at or over 25 IU/L of blood were predictive of cancer risk. This is less than the 40 IU/L commonly defined as the upper limit of normal levels. [3] Therefore NASH patients should target to maintain a low ALT level and do regular checkups.

Currently, there is no conventional medical therapy to lower ALT level in NASH patients as the cause is not yet known. NASH patients are generally advised to follow a healthy diet and do exercise; if you are overweight or obese, losing weight may also help to reduce fat in the liver which may reduce ALT level. [4] Apart from these standard recommendations, NASH patients should also focus on protecting their liver and preventing progression of the disease.

A clinical study on PubMed suggests that YHK, a natural alternative therapy, has an inhibitory effect on the development of NASH; it has been proven to effectively reduce inflammation in the liver and help liver cells recover. Research shows that over 80% of patients’ ALT normalized within 2 weeks of using YHK. [5][6][7]

In addition, it is also important for NASH patients to avoid the use of alcohol and unnecessary medications as these may hurt the liver further.

Reference:
  1. Liver Blood Tests. (2015). Retrieved from http://www.medicinenet.com/liver_blood_tests/article.htm (accessed 12/10/2015)
  2. ALT. (2013). Retrieved from https://www.nlm.nih.gov/medlineplus/ency/article/003473.htm (accessed 13/10/2015)
  3. Common medical screen predicts liver cancer risk in general population. (2012). Retrieved from http://www.mdanderson.org/newsroom/news-releases/2012/common-medical-screen-predicts-liver-cancer-risk-in-general-population.html (accessed 17/10/2015)
  4. Nonalcoholic Steatohepatitis. (2006). Retrieved from http://www.niddk.nih.gov/health-information/health-topics/liver-disease/nonalcoholic-steatohepatitis/Pages/facts.aspx (accessed 13/10/2015)
  5. Chande N, Laidlaw M, Adams P, Marotta P. (2006) “Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study” Digestive Diseases and Sciences Jul;51(7):1183-9. PMID: 16944007
  6. Stefano JT, de Oliveira CP, Corrêa-Giannella ML, de Lima VM, de Sá SV, de Oliveira EP, de Mello ES, Giannella-Neto D, Alves VA, Carrilho FJ. (2007) “Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP)” Digestive Diseases and Sciences Dec;52(12):3448-54. PMID: 17394061
  7. de Lima VM, de Oliveira CP, Sawada LY, Barbeiro HV, de Mello ES, Soriano FG, Alves VA, Caldwell SH, Carrilho FJ. (2007) “Yo jyo hen shi ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient diet” Liver International Mar;27(2):227-34. PMID: 17311618
Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
A:
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common liver diseases. They occur in people who drink little or no alcohol at all and are considered to be consequences of obesity.    However, “not obese” does not equal “no NAFLD / NASH”, since NAFLD may not be linked with obesity in some cases. Fatty liver disease may also develop in non-obese people. The terms “lean NAFLD” and “lean
Hit Questions
A:
YHK has significant effect in stopping liver inflammation; it can enhance the recovery of liver health and protect liver cells. Those who have experienced YHK often have these questions in mind: Why is YHK so different from other liver medicines and supplements? Why is it possible to have such unprecedented effects? The answer seems magical, but in fact, it is not complicated - Because YHK possesses a perfect balance.   To explain this, we must first point out that YH
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us